ArticleJournal of translational medicine2022

Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.

Yali Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.